- Home
- ACXP vs SLGL Comparison
ACXP vs SLGL Comparison
Compare ACXP & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACXP | SLGL |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 117.8M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ACXP | SLGL |
|---|---|---|
| Price | $3.63 | $39.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $143.67 | $50.00 |
| AVG Volume (30 Days) | ★ 78.0K | 15.3K |
| Earning Date | 11-12-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 62.04 |
| 52 Week Low | $3.17 | $4.02 |
| 52 Week High | $25.00 | $52.26 |
Technical Indicators
Market Signals| Indicator | ACXP | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 54.64 |
| Support Level | $3.98 | $38.30 |
| Resistance Level | $4.36 | $44.04 |
| Average True Range (ATR) | 0.36 | 3.60 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 21.60 | 60.95 |
Price Performance
Historical ComparisonAbout ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.